Bruna Pellini

Universidade Federal do Rio Grande — Brazil

Medicine · Health Sciences

18h-index900citations81works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(39), Cancer Genomics and Diagnostics(26), Lung Cancer Research Studies(14), Cancer Immunotherapy and Biomarkers(11), Lung Cancer Diagnosis and Treatment(7)

Publications81 total

Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use
Clinical Lung Cancer·2025
P3.18.61 KRYSTAL-4: Phase 3 Study of Adagrasib Plus Pembrolizumab and Chemotherapy Intreatment-Naïve, Advanced KRAG12C-Mutated NSCLC
Journal of Thoracic Oncology·2025· 1 cited
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
Journal of Clinical Oncology·2025· 5 cited
The state of the art in Blue Amazon biodiversity: Protocol for a systematic review
MethodsX·2025Open Access
Real World Safety of Tarlatamab Step-Up Dosing in Extensive Stage Small Cell Lung Cancer
Journal of Thoracic Oncology·2025· 1 cited
Empowering minority patients: A tailored education initiative for clinical trial awareness in thoracic oncology.
Journal of Clinical Oncology·2025
Chemotherapy plus anti-PD-1 or anti-PD-L1 in advanced PD-L1–negative squamous cell lung carcinoma: A systematic review and meta-analysis.
Journal of Clinical Oncology·2025
Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1–Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
Clinical Lung Cancer·2025· 1 cited
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation
Cell Reports Medicine·2025· 4 citedOpen Access
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3
Journal of Clinical Oncology·2025· 10 cited
Trastuzumab Deruxtecan Combination Strongly Enhances Responses and Overcomes Sotorasib Resistance in <i>KRAS</i> <sup>G12C</sup> -Mutant NSCLC
2024· 1 citedOpen Access
Computational Variant Origin Prediction (VOP) to distinguish germline, tumor somatic, and Clonal Hematopoiesis (CH) variants in Liquid Biopsy (LBX)
The Journal of Liquid Biopsy·2024Open Access
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Lung Cancer·2024· 9 cited
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve <i>EGFR</i> -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)
Journal of Clinical Oncology·2024· 34 citedOpen Access
P1.06C.02 Description of A Single Center Thoracic Rapid Tissue Donation Program Experience
Journal of Thoracic Oncology·2024Open Access
Discrepancy Between Liquid Biopsy and Tumor Next-Generation Sequencing Due to Low Tumor Fraction in a Patient With Lung Adenocarcinoma
Cureus·2024Open Access
Rapid Autopsy to Define Dendritic Cell Spatial Distribution and T Cell Association in Lung Adenocarcinoma
The Journal of Immunology·2024Open Access
Circulating tumor DNA kinetics: A future tool for radiation therapy personalization in lung cancer?
The Journal of Liquid Biopsy·2024· 3 citedOpen Access
A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study.
Journal of Clinical Oncology·2024· 18 cited
A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer (SqCLC).
Journal of Clinical Oncology·2024· 1 cited
page 1 of 5Next →

Frequent Co-authors

Aadel A. Chaudhuri(12), Pasi A. Jänne(6), Jhanelle E. Gray(6), Eric B. Haura(6), Siddhartha Devarakonda(5), Ramaswamy Govindan(5), Saiama N. Waqar(5), Misty Dawn Shields(4), Jeffrey J. Szymanski(4), Peter K. Harris(4), Alberto Chiappori(4), Ben Creelan(4), Tawee Tanvetyanon(4), Andreas Saltos(4), Daniel Morgensztern(4), Lyudmila Bazhenova(4), Julian A. Marin‐Acevedo(3), Nicholas P. Semenkovich(3), Pradeep S. Chauhan(3), Nadja Pejovic(3)